Shares of Solid Biosciences (NASDAQ:SLDB) jumped ~88% in the premarket on Tuesday after the gene therapy developer reported ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data.

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...

Solid Biosciences has reported promising initial findings from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, a gene therapy aimed at treating Duchenne muscular dystrophy. Data from the first ...

Boston, USA-based biotech Solid Biosciences saw its shares rocket 36% to $5.48 yesterday, after the precision genetic ...

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

Solid Biosciences (SLDB) announced initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy ...

The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% ...

Investing.com -- Shares of Solid Biosciences Inc ... Analysts have taken note of the data's implications for the Duchenne muscular dystrophy (DMD) treatment landscape. Truist analyst Joon ...